Credit Suisse Ag Entrada Therapeutics, Inc. Call Options Transaction History
Credit Suisse Ag
- $101 Billion
- Q1 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding TRDA
# of Institutions
85Shares Held
27.7MCall Options Held
100Put Options Held
0-
Baker Bros. Advisors LP New York, NY4.87MShares$80 Million0.92% of portfolio
-
Mpm Asset Management LLC Cambridge, MA4.43MShares$72.8 Million34.63% of portfolio
-
5 Am Venture Management, LLC San Francisco, CA4.41MShares$72.5 Million29.39% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD3.13MShares$51.5 Million0.01% of portfolio
-
Black Rock Inc. New York, NY1.69MShares$27.8 Million0.0% of portfolio
About Entrada Therapeutics, Inc.
- Ticker TRDA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 31,368,500
- Market Cap $516M
- Description
- Entrada Therapeutics, Inc., a biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its endosomal escape vehicle platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. The company's lead product candidate is ENTR-601-44, which is in precli...